Healx, a clinical-stage biotech company specialising in rare diseases, has announced an agreement with Sanofi to utilize a Sanofi compound in identifying new disease indications using Healnet, Healx’s AI-driven drug discovery platform. The financial terms of the partnership have not been disclosed.
Company Information
Company
Healx
Location
Cambridge, England, United Kingdom
About
Healx is an AI-enabled, clinical-stage biotech company specializing in rare diseases. Co-founded by its chairman David Brown and Tim Guilliams, its mission is to apply emerging technologies to accelerate the discovery of treatments for rare diseases. The company's pipeline includes innovative therapies targeting conditions such as neurofibromatosis Type 1, utilizing their proprietary Healnet discovery platform. Healx is committed to harnessing AI to identify and develop new therapeutic opportunities for patients with significant unmet medical needs.